April 1st, 2026

Company Name: GENOVA Inc.
Representative: President and Representative Director, Tomoki Hirase
(Ticker: 9341: Tokyo Stock Exchange Prime Market)
Inquiries: Board Director and Executive Officer, Akinao Ueda

Notice Regarding the Acquisition of Akasaka Shizaisha Co., Ltd. (conversion into a Subsidiary)

We hereby announce that at the Board of Directors meeting held on April 1, 2026, we resolved to acquire Akasaka Shizaisha Co., Ltd. (Representative Director and President: Hiroyuki Akasaka; hereinafter "Akasaka Shizaisha") and make it a subsidiary. The details of the acquisition are outlined below.

1. Purpose of the Acquisition

Under our mission of "Creating a Healthy Society by Connecting People and Medical Care," we are committed to "Creating the 21st Century Medical Care Infrastructure" and are striving for "Maximizing Clinic Productivity and Patient Convenience through Clinic Automation." In April 2025, we established a new subsidiary and entered the dental distribution business by taking over operations related to the development and sales of dental medical equipment, instruments, materials, and pharmaceuticals. Through this initiative, we are solving issues in the medical field and creating new value by building an optimal supply chain in dental distribution and collaborating with our group's marketing and digital transformation (DX) domains.

Akasaka Shizaisha is a company that provides dental material wholesale services primarily targeting dental technicians. The company's strength lies in its deep engagement and strong relationships with customers cultivated over many years, making it an indispensable partner in the industry.

Through this transaction, ASANO's extensive dental distribution network will be integrated with Akasaka Shizaisha's specialized logistics network in the dental technology field. By

building a robust supply chain that encompasses everything from dental clinics to dental laboratories, we believe this will establish a system to support Japan's dental healthcare infrastructure more stably and efficiently from a "logistics" perspective.

By welcoming Akasaka Shizaisha into our group, we anticipate synergies not only within the dental distribution business but also across our other operations. We believe this will enable us to further expand our business foundation and achieve greater management efficiency.

2. Overview of the Target Company (Akasaka Shizaisha Co., Ltd.)

(1) Name	Akasaka Shizaisha Co., Ltd.		
(2) Location	3-13-6 Minamiotsuka, Kawagoe City, Saitama		
(3) Title and Name of Representative	Hiroyuki Akasaka, Representative Director and President		
(4) Description of Business	Sales of dental materials		
(5) Capital	9 million yen		
(6) Date of Establishment	May 19, 1980		
(7) Major Shareholders and Shareholding Ratios	Hiroyuki Akasaka: 4,100 shares (45.56%) Masanori Akasaka: 4,100 shares (45.56%) Takeo Akasaka: 800 shares (8.88%)		
(8) Relationship between us and the target company	Capital Relationship	Not applicable	
	Personnel Relationship	Not applicable	
	Business Relationship	Not applicable	
(9) Operating Results and Financial Position of the Target Company for the Last Three Years			
Fiscal Year Ended	April 20, 2023	April 20, 2024	April 20, 2025
Net Assets	118,460 thousand yen	148,444 thousand yen	168,741 thousand yen
Total Assets	923,445 thousand yen	1,021,184 thousand yen	1,123,925 thousand yen
Net Assets per Share	13,162 yen	16,493 yen	18,749 yen
Net Sales	4,887,876 thousand yen	4,982,635 thousand yen	5,760,388 thousand yen
Operating Profit	54,068 thousand yen	39,395 thousand yen	24,361 thousand yen
Ordinary Profit	53,704 thousand yen	40,055 thousand yen	23,727 thousand yen

Net Income	38,104 thousand yen	29,984 thousand yen	20,297 thousand yen
Net Income per Share	4,233 yen	3,331 yen	2,255 yen

(Note: The financial figures are unaudited.)

3. Overview of the Counterparties to the Acquisition of Equity Interests

(1) Name and Address	Hiroyuki Akasaka (Kawagoe City, Saitama) Masanori Akasaka (Kawagoe City, Saitama) Takeo Akasaka (Kawagoe City, Saitama)
(2) Relationship between us and the individuals	There are no capital, personnel, or business relationships to be stated.

4. Number of Shares to be Acquired, Acquisition Cost, and Shareholding Ratio Before and After the Acquisition

(1) Number of shares held before the transfer	- shares (Number of voting rights: -) (Voting rights ratio: -%)		
(2) Number of shares to be acquired	9,000 shares		
(3) Acquisition cost	Ordinary shares of the target company Advisory expenses, etc. (estimated amount) Total (estimated amount)	600 million yen 13 million yen 613 million yen	(note)
(4) Number of shares held after the transfer	9,000 株 (Number of voting rights: 9,000) (Voting rights ratio: 100%)		

(Note) To ensure fairness and appropriateness, the acquisition cost of the shares was determined based on a shareholder value assessment, financial due diligence, and legal due diligence conducted by external institutions, as well as through negotiations and agreement with the counterparties to the share acquisition, Mr. Hiroyuki Akasaka, Mr. Masanori Akasaka, and Mr. Takeo Akasaka.

5. Schedule

(1) Date of Board of Directors' resolution	April 1, 2026
(2) Date of contract execution	April 1, 2026
(3) Execution date of share transfer	April 21, 2026 (Scheduled)

6. Future Outlook

As a result of this acquisition of equity interests, Akasaka Shizaisha is scheduled to become our consolidated subsidiary from the second quarter of the fiscal year ending March 2027. The impact of this share acquisition on our business results and financial position for the fiscal year ending March 2026 is currently under examination. We will promptly announce any matters that require disclosure in the future.